In 2021, Mydecine made significant progress in creating and commercializing new treatments for mental health and addiction disorders It also made a noteworthy shift in focus to reducing expenses and increasing efficiencies for continued clinical trials and the expansion of its IP portfolio For 2022, the company plans to build on the progress achieved in … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Provides Business Update, Marking 2021 Achievements”
Mainstream acceptance of psychedelics took a “significant leap forward” with study results published in “Nature Medicine” Many say it is only a matter of time before FDA grants approval for psychoactive compounds to be used therapeutically SILO is focused on merging traditional therapeutics with psychedelic research for people suffering from underserved indications “The Psychedelic Revolution … Continue reading “Silo Pharma Inc. (SILO) Emerging Leader as Psychedelics ‘on the Cusp of Entering Mainstream Psychiatry’”
Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial … Continue reading “NetworkNewsBreaks – Why Silo Pharma Inc. (SILO) Is ‘One to Watch’”
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products, such as psychedelics and cannabis, for the market. The company understands that research is integral for the rapidly developing psychedelics and cannabis industries, and for … Continue reading “NetworkNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Boundaries in Research of New Products”
Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences Conference In presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the year During a … Continue reading “Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022”
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option … Continue reading “NetworkNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces New Clinic Openings as Company’s Expansion Accelerates”
Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its treatment options to include SPRAVATO(R) nasal spray. KWC clinics located in Houston, Las Vegas and Seattle will begin offering this treatment option on April 1. According to the announcement, SPRAVATO is … Continue reading “NetworkNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Treatment Options to Add FDA-Approved Esketamine Nasal Spray”
Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The … Continue reading “Silo Pharma Inc. (SILO) Is ‘One to Watch’”
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders. These strategic moves include developing drug candidates, … Continue reading “NetworkNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Moving to Become Trusted Source of Effective Medication-Based Treatments”
Designed to merge ideas with investment, NobleCon18 (the first full in-person NobleCon since February 2020) will feature 100+ carefully selected emerging growth public companies. With total attendance limited to 1,000, this ideal-sized event will provide investors with more direct access to executive teams over the course of the two-day conference. Taking place at The Guitar … Continue reading “Sneak Peek at NobleCon18’s Current Lineup of Keynotes & Moderators”
